Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV is positioned for significant financial growth, with an increased global peak sales estimate for its oral bradykinin B2 receptor antagonist, deucrictibant, projected to reach $1.65 billion by 2037. The promising Phase 2 data demonstrated substantial quality of life improvements, as evidenced by 100% of patients achieving "well-controlled HAE" status on the Angioedema Control Test and reporting enhanced health-related quality of life. Furthermore, the lack of approved therapies for HAE, coupled with a prevalence rate of approximately 1:100,000 to 1:500,000, suggests that deucrictibant could capture a significant market share if regulatory approval is obtained.

Pharvaris NV faces fundamental challenges that contribute to a negative outlook on its stock. The lack of adequate de-risking for bradykinin B2 receptor antagonism in chronic prophylaxis raises concerns about the efficacy and safety of its lead product, deucrictibant, in a competitive market dominated by established therapies. Additionally, the emergence of multiple subcutaneous therapies likely to be approved in the near future may further erode Pharvaris's market share and limit the adoption of its treatment.